Background and Objectives: Epidemiologic data on hospitalizations for acute pericarditis are scarce. We sought to study the trends in these hospitalizations and outcomes in the USA over a 10-year period. Methods: We used the 2003-2012 Nationwide Inpatient Sample database to identify admissions with a primary diagnosis of acute pericarditis. Outcomes included hospitalization rate, case fatality rate (CFR), length of stay (LOS), hospital charges, complications and diagnostic and therapeutic procedures. Results: We observed an estimated 135,710 hospitalizations for acute pericarditis among patients ≥16 years during the study period (mean age 53.5 ± 18.5 years; 40.5% women). The incidence of acute pericarditis hospitalizations was significantly higher for men than for women [incidence rate ratio (IRR) 1.56; 95% confidence interval (CI) 1.54-1.58; p < 0.001]; it decreased from 66 to 54 per million person-years (p < 0.001). CFR and LOS declined significantly during the study period (CFR: 2.2% in 2003 to 1.4% in 2012; LOS: 4.8 days in 2003 to 4.1 days in 2012; p < 0.001 for both). The average inflation-adjusted health-care charge increased from USD 31,242 to 38,947 (p < 0.001). Conclusion: The hospitalization rate, CFR and LOS associated with acute pericarditis have declined significantly in the US population. Average charges for acute pericarditis hospitalization have increased.

1.
LeWinter MM: Clinical practice. Acute pericarditis. N Engl J Med 2014;371:2410-2416.
2.
Adler Y, Finkelstein Y, Guindo J, Rodriguez de la Serna A, Shoenfeld Y, Bayes-Genis A, Sagie A, Bayes de Luna A, Spodick DH: Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation 1998;97:2183-2185.
3.
Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G: Relapsing pericarditis. Heart 2004;90:1364-1368.
4.
Imazio M, Demichelis B, Parrini I, Cecchi E, Demarie D, Ghisio A, Belli R, Bobbio M, Trinchero R: Management, risk factors, and outcomes in recurrent pericarditis. Am J Cardiol 2005;96:736-739.
5.
Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmüller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH; Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology: Guidelines on the diagnosis and management of pericardial diseases: executive summary. Eur Heart J 2004;25:587-610.
6.
Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, Cumetti D, Varbella F, Trinchero R, Spodick DH, Adler Y: Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014;383:2232-2237.
7.
Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, Ghisio A, Belli R, Trinchero R: Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005;165:1987-1991.
8.
Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, Demarie D, Forno D, Ferro S, Maestroni S, Belli R, Trinchero R, Spodick DH, Adler Y; ICAP Investigators: A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013;369:1522-1528.
9.
Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R: Colchicine in addition to conventional therapy for acute pericarditis: results of the Colchicine for acute PEricarditis (COPE) trial. Circulation 2005;112:2012-2016.
10.
Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y; CORP Investigators: Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011;155:409-414.
11.
Imazio M, Brucato A, Belli R, Forno D, Ferro S, Trinchero R, Adler Y: Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis. J Cardiovasc Med (Hagerstown) 2014;15:840-846.
12.
13.
14.
Kytö V, Sipilä J, Rautava P: Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation 2014;130:1601-1606.
15.
Census.gov (accessed October 14, 2014). http://www.census.gov.
16.
STATA/Data analysis and statistical software (accessed January 8, 2014). http://www.stata.com.
17.
Lin AH, Phan H-AL, Barthel RV, Maisel AS, Crum-Cianflone NF, Maves RC, Nayak KR: Myopericarditis and pericarditis in the deployed military member: a retrospective series. Mil Med 2013;178:18-20.
18.
Imazio M, Cecchi E, Demichelis B, Chinaglia A, Ierna S, Demarie D, Ghisio A, Pomari F, Belli R, Trinchero R: Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008;94:498-501.
19.
Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Barrett MA, Rose NR, Fairweather D: Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 2007;178:6710-6714.
20.
Frisancho-Kiss S, Coronado MJ, Frisancho JA, Lau VM, Rose NR, Klein SL, Fairweather D: Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun 2009;23:649-657.
21.
Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y: Controversial issues in the management of pericardial diseases. Circulation 2010;121:916-928.
22.
Guindo J, Rodriguez de la Serna A, Ramió J, de Miguel Diaz MA, Subirana MT, Perez Ayuso MJ, Cosín J, Bayes de Luna A: Recurrent pericarditis. Relief with colchicine. Circulation 1990;82:1117-1120.
23.
Millaire A, de Groote P, Decoulx E, Goullard L, Ducloux G: Treatment of recurrent pericarditis with colchicine. Eur Heart J 1994;15:120-124.
24.
Brucato A, Cimaz R, Balla E: Prevention of recurrences of corticosteroid-dependent idiopathic pericarditis by colchicine in an adolescent patient. Pediatr Cardiol 2000;21:395-396.
25.
Millaire A, Ducloux G: Treatment of acute or recurrent pericarditis with colchicine. Circulation 1991;83:1458-1459.
26.
Imazio M: Colchicine for pericarditis. Trends Cardiovasc Med 2015;25:129-136.
27.
Syed FF, Mayosi BM: Pharmacotherapy: colchicine for recurrent pericarditis - what's new in CORP-2? Nat Rev Cardiol 2014;11:376-378.
28.
Cacoub PP: Colchicine for treatment of acute or recurrent pericarditis. Lancet 2014;383:2193-2194.
29.
Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, Demarie D, Ghisio A, Trinchero R: Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004;43:1042-1046.
30.
Seferović PM, Ristić AD, Maksimović R, Simeunović DS, Milinković I, Seferović Mitrović JP, Kanjuh V, Pankuweit S, Maisch B: Pericardial syndromes: an update after the ESC guidelines 2004. Heart Fail Rev 2013;18:255-266.
31.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, Turner MB: Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation 2015;131:e29-e322.
32.
Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA: Centers for Disease Control and Prevention. Enterovirus surveillance - United States, 1970-2005. MMWR Surveill Summ 2006;55:1-20.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.